FDA’s Pazdur Tapped For New Oncology Office Director
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncology division head Pazdur is selected to lead FDA’s new Office of Oncology Drug Products following national search. Pazdur will begin assuming duties of the office May 1; the office will officially launch in July as part of a broader Office of New Drugs reorganization.
You may also be interested in...
FDA Gastroenterology Drugs Division Headed By Harvey; Phase-Out Of ODE V Complete
Harvey brings GI experience from the device center as former Gastroenterology & Renal Devices Branch reviewer. His appointment comes as FDA is eliminating the Office of Drug Evaluation V under the reorganization of the Office of New Drugs.
FDA Gastroenterology Drugs Division Headed By Harvey; Phase-Out Of ODE V Complete
Harvey brings GI experience from the device center as former Gastroenterology & Renal Devices Branch reviewer. His appointment comes as FDA is eliminating the Office of Drug Evaluation V under the reorganization of the Office of New Drugs.
HHS Secretary Leavitt Opens FDA Science Forum April 27
Annual event includes an update on the new Office of Oncology Products, a “Meet the Center Directors” session, and panels on post-marketing risk management and biological product safety.